About Stellar Biotechnologies (NASDAQ:SBOT)
Stellar Biotechnologies, Inc. is a biotechnology company. The Company is engaged in the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (KLH). KLH is an immune-stimulating protein. KLH can be used as an active pharmaceutical ingredient (API) and combined with a disease-targeting agent to create immunotherapies for the treatment of a range of diseases. The Company's core business is developing and commercializing Keyhole Limpet Hemocyanin for use in immunotherapy and immunodiagnostic applications. The Company's Stellar KLH product offerings include Stellar KLH protein for conjugation and as carrier molecule in immunotherapy development; Stellar KLH protein and enzyme-linked immunosorbent assay (ELISA) test kits for immune function testing, and Custom KLH formulations, adjuvants, conjugations and fill finishes for preclinical research and drug development applications.
Industry, Sector and Symbol:
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Sector: Biotechnology & Medical Research - NEC
- Symbol: NASDAQ:SBOT
- CUSIP: N/A
- Web: stellarbiotechnologies.com
- Current Ratio: 19.31%
- Quick Ratio: 18.98%
Sales & Book Value:
- Annual Sales: $1.27 million
- Price / Sales: 8.95
- Book Value: $1.21 per share
- Price / Book: 0.89
- Trailing EPS: ($0.51)
- Net Income: ($5,020,000.00)
- Net Margins: -1,025.65%
- Return on Equity: -49.68%
- Return on Assets: -47.30%
- Employees: 23
- Outstanding Shares: 10,520,000
Frequently Asked Questions for Stellar Biotechnologies (NASDAQ:SBOT)
What is Stellar Biotechnologies' stock symbol?
Stellar Biotechnologies trades on the NASDAQ under the ticker symbol "SBOT."
How were Stellar Biotechnologies' earnings last quarter?
Stellar Biotechnologies, Inc. (NASDAQ:SBOT) issued its earnings results on Tuesday, May, 9th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.15) by $0.04. The biotechnology company had revenue of $0.06 million for the quarter, compared to analysts' expectations of $0.33 million. Stellar Biotechnologies had a negative return on equity of 49.68% and a negative net margin of 1,025.65%. View Stellar Biotechnologies' Earnings History.
When will Stellar Biotechnologies make its next earnings announcement?
Where is Stellar Biotechnologies' stock going? Where will Stellar Biotechnologies' stock price be in 2017?
1 equities research analysts have issued 12-month price objectives for Stellar Biotechnologies' shares. Their forecasts range from $4.00 to $4.00. On average, they expect Stellar Biotechnologies' share price to reach $4.00 in the next year. View Analyst Ratings for Stellar Biotechnologies.
Who are some of Stellar Biotechnologies' key competitors?
Some companies that are related to Stellar Biotechnologies include Can Fite Biopharma Ltd (CANF), Fibrocell Science (FCSC), Oxford Pharmascience Group Plc (OXP), Burcon NutraScience Corp (BUR), OncoGenex Pharmaceuticals (ACHV), Repros Therapeutics (RPRX), Synairgen plc (SNG), OpGen (OPGN), RXi Pharmaceuticals Corporation (RXII), Novogen Limited (NVGN), Transgenomic (PRPO), Jaguar Animal Health (JAGX), Metabolix (YTEN), Senestech (SNES), Ixico Plc (IXI), Ampliphi Biosciences Corp (APHB), ImmunoCellular Therapeutics Ltd (IMUC) and Sorrento Tech (ROKA).
Who are Stellar Biotechnologies' key executives?
Stellar Biotechnologies' management team includes the folowing people:
- Frank R. Oakes, Chairman of the Board, President, Chief Executive Officer (Age 65)
- Kathi Niffenegger CPA, Chief Financial Officer, Secretary (Age 58)
- Gregory T. Baxter Ph.D., Executive Vice President - Corporate Development (Age 57)
- Tessie Mary Che Ph.D., Director (Age 65)
- Paul Chun, Director
- Daniel E. Morse Ph.D., Director (Age 74)
- Charles Olson, Director
- David L. Hill Ph.D., Independent Director (Age 65)
How do I buy Stellar Biotechnologies stock?
Shares of Stellar Biotechnologies can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Stellar Biotechnologies' stock price today?
One share of Stellar Biotechnologies stock can currently be purchased for approximately $1.08.
How big of a company is Stellar Biotechnologies?
Stellar Biotechnologies has a market capitalization of $12.2 million and generates $1.27 million in revenue each year. The biotechnology company earns ($5,020,000.00) in net income (profit) each year or ($0.51) on an earnings per share basis. Stellar Biotechnologies employs 23 workers across the globe.
How can I contact Stellar Biotechnologies?
MarketBeat Community Rating for Stellar Biotechnologies (NASDAQ SBOT)MarketBeat's community ratings are surveys of what our community members think about Stellar Biotechnologies and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Stellar Biotechnologies' mailing address is 332 E Scott St, PORT HUENEME, CA 93041-2939, United States. The biotechnology company can be reached via phone at +1-805-4882800 or via email at [email protected]
Analysts' Consensus Ratings for Stellar Biotechnologies (NASDAQ:SBOT) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 1 Buy Rating, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$4.00 (270.37% upside)|Consensus Price Target History for Stellar Biotechnologies (NASDAQ:SBOT)
Analysts' Ratings History for Stellar Biotechnologies (NASDAQ:SBOT)
(Data available from 11/17/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|12/2/2016||Maxim Group||Lower Price Target||Buy||$7.00 -> $4.00||N/A|
Earnings History for Stellar Biotechnologies (NASDAQ:SBOT)Earnings History by Quarter for Stellar Biotechnologies (NASDAQ SBOT)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/9/2017||Q3 2017||($0.12)||($0.12)||$0.34 million||$0.02 million||View||N/A|
|5/9/2017||Q2 2017||($0.15)||($0.11)||$0.33 million||$0.06 million||View||N/A|
|2/6/2017||Q1 2017||($0.10)||($0.15)||$0.31 million||$0.14 million||View||N/A|
Earnings Estimates for Stellar Biotechnologies (NASDAQ:SBOT)
2017 EPS Consensus Estimate: ($0.60)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Stellar Biotechnologies (NASDAQ:SBOT)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Stellar Biotechnologies (NASDAQ SBOT)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Stellar Biotechnologies (NASDAQ:SBOT)
Latest Headlines for Stellar Biotechnologies (NASDAQ SBOT)
|Should You Buy Stellar Biotechnologies Inc (SBOT) Now?|
finance.yahoo.com - October 18 at 1:42 AM
|SBOT: Neovacs Ph 2 Lupus Study Completes Enrollment. Read-Out Q2 2018|
finance.yahoo.com - September 6 at 8:00 AM
|Stellar Biotechnologies, Inc. :SBOT-US: Earnings Analysis: Q3, 2017 By the Numbers : August 24, 2017|
finance.yahoo.com - August 25 at 11:22 AM
|Stellar Biotechnologies, Inc. (SBOT) Releases Quarterly Earnings Results, Hits Estimates|
www.americanbankingnews.com - August 10 at 11:28 PM
|Stellar Biotechnologies Reports Third Quarter 2017 Financial Results - PR Newswire (press release)|
www.prnewswire.com - August 10 at 8:20 PM
|Stellar Biotechnologies Reports Third Quarter 2017 Financial Results|
finance.yahoo.com - August 10 at 7:41 AM
|Stellar Biotechnologies, Inc. (NASDAQ:SBOT) to Release Earnings on Monday|
www.americanbankingnews.com - July 31 at 11:40 AM
|Stellar Biotechnologies Expands Operations Team - PR Newswire (press release)|
www.prnewswire.com - June 8 at 3:00 AM
|Stellar Biotechnologies Reports Second Quarter 2017 Financial Results - PR Newswire (press release)|
www.prnewswire.com - May 10 at 11:02 AM
|STELLAR BIOTECHNOLOGIES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to|
biz.yahoo.com - March 29 at 8:32 AM
|Stellar Biotechnologies (SBOT) to Sell 'Immunogen & Vaccine Technology' to Matrivax|
www.streetinsider.com - March 13 at 7:24 PM
|Stellar Biotechnologies and Matrivax Sign Agreement to Transfer Vaccine Technology|
us.rd.yahoo.com - March 13 at 7:24 PM
|STELLAR BIOTECHNOLOGIES, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Other Events, Finan|
biz.yahoo.com - March 13 at 7:24 PM
|Amaran Biotechnology Selects Stellar KLH for Cancer Vaccines - PR Newswire (press release)|
www.prnewswire.com - March 2 at 1:02 AM
|Amaran Biotechnology Selects Stellar KLH for Cancer Vaccines|
us.rd.yahoo.com - March 1 at 10:06 AM
|Stellar Biotechnologies Reports First Quarter 2017 Financial Results - PR Newswire (press release)|
www.prnewswire.com - February 7 at 8:08 AM
|8:24 am Stellar Biotechnologies issues a statement congratulating Neovacs S.A. for its decision to extend the development of its lupus drug for Type 1 diabetes|
us.rd.yahoo.com - February 7 at 12:53 AM
|STELLAR BIOTECHNOLOGIES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements|
biz.yahoo.com - December 14 at 10:01 PM
|STELLAR BIOTECHNOLOGIES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial|
biz.yahoo.com - December 9 at 7:36 PM
Stellar Biotechnologies (NASDAQ SBOT) Chart for Friday, November, 17, 2017